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Abstract—The accurate identification of drug side effects
represents a major concern for public health. We propose a
collaborative filtering model for large-scale prediction of drug
side effects. Our approach provides side effects recommendations
for drugs to safety professionals. The proposed latent factor
model relies solely on the public drug-side effect relationships
from safety data. Applied to 1,525 marketed drugs and 2,050 side
effect terms, we achieved an AUPRC (area under the precision-
recall curve) of 0.342 in a test set, with a sensitivity of 0.73 given a
specificity of 0.95, providing state-of-the-art performance in side
effect prediction. We analyze the performance of the method
on drug-specific Anatomical Therapeutic and Chemical (ATC)
category and side effect- specific medical category of disorders.
Our findings suggest that latent factor models can be useful for
the early and accurate detection of unknown adverse drug events.
Index Terms—drug, side effects, recommendation systems,
adverse drug events, latent factor model, collaborative filtering
I. INTRODUCTION AND RELATED WORK
Drug side effects represent one of the leading causes of mor-
bidity and mortality in health care [1]. The American Institute
of Medicine reported that 100,000 deaths occur annually in
the U.S. from medical errors, many of which are caused by
unexpected drug side effects [2]. Side effects of drugs also
represent a major cost for public health. For instance, in the
USA only, health care surcharge is about US $136B yearly
[3]. Consequences of side effects can also affect the pharma
industry. In fact, major financial setbacks could occur after a
marketed drug is forced to withdraw due to deadly side effects
[4]. A famous case occurred in 2004 when Merck & Co had
to pull out its arthritis drug Vioxx from the market because
experiments from clinical trials showed an increased risk of
heart attack and stroke [5].
The detection of drug side effects starts early in the pre-
marketing stage, where the molecular entity (later on, com-
mercial drug) undergoes extensive toxicity assessment in vitro,
in vivo in animal models and, after approval from the corre-
sponding agency such as the Food and Drug Administration
(FDA) in the USA, in human clinical trials [6]. In spite of this
effort, many side effects are not detected until the drug hits the
market. For this reason, post-marketing surveillance systems,
such as the FDA-Adverse Event Reporting System, are used
to follow-up the drug response in the treated population.
In silico methods for side effect identification have been
proposed to help identify the most likely side effect candidates
for drugs [7]–[11]. One group of methods relies on the
structural chemistry of the drug and on the protein target
profiles. For instance, Lounkine et al. [7] predicted drug-target-
side effect associations using a similarity-ensemble approach
(SEA). SEA calculates whether a molecule will bind to a
target based on the chemical features it shares with those
of known ligands, using a statistical model to control for
random similarity [12]. Yamanishi et al. [8] predicted drug-
side effect associations by an integrative approach based on
kernel regression models that rely on chemical structures and
target proteins. LaBute et al. [9] predicted drug-side effect
associations by virtually screening drug off-target associations
using molecular docking. Although these methods, that rely on
molecular or protein structure, offer biological interpretabil-
ity, they are often limited to the set of known structures,
require considerable computational power, and generate a large
amount of false positives [13].
Another group of methods frames the side effect prediction
problem as infering missing links in a drug-side effect bipartite
network. Cami et al. [10] proposed a missing link prediction
method called Predictive Pharmacosafety Networks (PPNs).
PPNs exploits the structure of the binary bipartite drug-side
effect network by defining several covariates that are combined
in a multivariate logistic regression model. The model outputs
a probability score for each missing link in the bipartite
network. The advantage of PPNs is that it relies on known drug
safety relationships to make accurate predictions of missing
associations. In fact, in silico methods can further strengthen
the current drug safety toolkit by serving as hypothesis genera-
tor to drug safety professionals. The method we present in this
paper, belongs to this second group of methods and we predict
missing links by using a collaborative filtering approach which
was developed recently for recommending movies to users.
Collaborative filtering methods became popular during the
2006 Netflix Inc. Prize Competition. Netflix released data on
users preferences on movies [14]. The competition ignited
an unprecedented interest and advancement in the field of
recommendation systems [15], [16]. In particular, latent fac-
tor models have been shown to provide good performance
over state-of-the-art methods in movie recommendation. These
methods are based on the idea that there is a common set of
hidden representations that can characterize the user-movies
preferences. Matrix decomposition techniques are widely used
to obtain these latent factors [17].
Importantly, there is a fundamental difference between the
side effect prediction and the movie recommendation prob-
lems. In movie recommendation, the fundamental assumption
is that any missing value is a potential rating value, i.e. an user
can watch any of the listed movies in the future. However,
drugs might not be able to produce any possible side effect
[18]. For instance, blood system drugs causes few sensory
and endocrine-related side effects, whereas anti-cancer drugs
produce side effects in almost all human systems [20].
In this paper, we propose a latent factor model to predict
unknown drug side effects. We show that our basic matrix
decomposition model outperforms PPNs. We also analyze
the drug- and side effect- specific category performances.
We argue that the latter analysis can be useful to safety
professionals interested in performing tailored predictions of
drug toxicity response. The structure of the rest of the paper
is as follows. First, we start with the mathematical framework
of matrix decomposition. Second, we show the evaluation
procedure and introduce the comparison method. Finally, we
showcase the data and the results of the predictions.
II. THE LATENT FACTOR MODEL
The matrix decomposition model is based on the assumption
that any m × n matrix R of rank k  min{m,n} can be
expressed in the following product form of rank-k factors [21]:
R ≈ Rˆ = PQ (1)
Here, P is a m× k matrix, and Q is a k×n matrix. In the
side effect prediction problem, R contains binary associations
for m marketed drugs and n side effect terms, i.e. ruj =
1 if the drug u is known to cause side effect j, otherwise
ruj = 0. In this model, P represents the drug latent space and
Q contains the side effects coefficients. The product PQ is
related to the probability that a given drug produces any of the
given side effects, as shown in Figure 1. The decomposition
in (1) can be obtained by minimizing the functional:
f(P,Q) =
1
2
‖R−PQ‖2F +
λ
2
(‖P‖2F + ‖Q‖2F ) (2)
where λ(‖P‖2F + ‖Q‖2F ) is an L2 regularization term
with penalty λ added to prevent over-fitting and ‖.‖F is the
Frobenius norm, defined as the square root of the sum of the
square of its elements. The difficulty of solving (2) is due to
the fact that the functional f(P,Q) is non-convex in both P
and Q. Thus, gradient descent-based methods are required to
approximate the solution. Thus, the derivatives of (2) are:
∂f(P,Q)
∂P
= −(R−PQ)QT + λP (3)
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〈rˆ〉 = pAQ
Fig. 1: The model is represented as a network depicting how
the side effects in the bottom layer are generated from the Drug
A hidden representations 〈pA〉 = p1, ..., pk in the top layer
nodes. In this illustration, pA is a row of P and 〈rˆ〉 = rˆ1, ..., rˆn
is a row of Rˆ. 〈rˆ〉 contains the scores for all the side effects
for the given drug.
∂f(P,Q)
∂Q
= −PT (R−PQ) + λQ (4)
We used conjugate gradient descent (CGD) and approxi-
mated line searches based on polynomial interpolation with
Wolfe-Powel conditions to find the local minima in (2). We
used a Matlab implementation of this minimizer [22]. We
initialized P and Q as normally distributed random variables
with small variance σ2 = 0.01. This is done to ensure that the
initial weights have small values. The learning plateaus after
roughly 300 iterations (max change in the matrices between
two consecutive iterations  < 10−4).
A. The evaluation
We evaluated the performance of our method using the
standard evaluation procedure for recommendation systems
[21], [23]–[25]. The known entries in the m×n binary matrix
R were randomly split into training T train and testing T test
sets. The training set T train contained 90% of the known
entries in R and T test only contained 10% of the entries. We
used T train in a ten-fold cross validation procedure for the
training of the parameters λ and k. For this procedure, we
randomly split the known entries in T train into ten disjoint
sets. For each set s, we trained the model with s− 1 sets and
tested on the remaining set. The optimal parameters (kop, λop)
are those that maximizes the mean AUROC for the ten folds.
Finally, the model performance was measured on T test by
training on the entire T train using the optimal parameters.
B. Predictive pharmacosafety networks (PPNs)
In order to make this paper self-contained, we introduce
in this subsection the state-of-the-art side effect prediction
method Predictive Pharmacosafety Networks (PPNs) [10]
which we use later for comparison. PPNs begins by creating a
bipartite graph in which one set of nodes represent the drugs
and the other set of nodes represent the side effects. The set of
edges corresponds to the known drug-side effect associations.
PPNs then computes covariate measures in this network to
capture the structure of connections between drugs and side
effects. The covariate Xs(u, j) quantify a relationship between
a drug node u and a side effect node j. The predictive model is
based on the binary response variable Yuj , u ∈ {1, ...,m}, j ∈
{1, ..., n}, for m drugs and n side effects. Yuj denotes the
presence or absence of drug-side effect associations. Using a
multivariate logistic-regression model, the response is modeled
as a Bernoulli random variable with the following expectation
E[Yuj ] =
1
1 + exp (−∑s βsXs(u, j)) (5)
where βs denotes the model parameter and Xs the model
covariate. The optimization is performed by assuming inde-
pendence between the responses Yij and performing model
fitting by maximum likelihood. Several covariates are consid-
ered in the PPN-NET model. The degree covariates are defined
as follow;
X1(u, j) = deg(u)× deg(j)
X2(u, j) = |deg(u)− deg(j)|
(6)
Here, deg(u) denotes the degree of node u. The degree
product covariate, X1(u, j), aimed to capture preferential
attachment among high-degree drugs and side effects. The
degree difference covariate, X2(u, j), aimed to capture as-
sortativity, i.e. whether high-degree drugs connects to high-
degree side effects or to small-degree side effects. The distance
covariates are also defined. These depends not only on the
nodes (u, j) but on the sets of neighbor N(u) and N(j). Let
J(j, k) denotes the Jaccard similarity between the neighbors
sets N(j) and N(k),
J(j, k) =
|N(j) ∩N(k)|
|N(j) ∪N(k)| (7)
The following Jaccard-based covariates quantify structural
similarity between drug pairs and side effect pairs,
X3(u, j) = max
k∈N(u)−{j}
{J(j, k)}
X4(u, j) = max
k∈N(j)−{u}
{J(u, k)} (8)
Finally, Jaccard-based predictors based on Kullback-Leibler
divergence (KL) between the overall distribution of similarities
between a drug (D¯se) and the drugs in its local neighborhood
(Dse(u, j)) or between side effects (D¯se) and side effects in
its neighborhood (Dse(u, j)) are defined;
X5(u, j) = KL(Dse(u, j), D¯se)
X6(u, j) = KL(Ddrug(u, j), D¯drug)
(9)
III. THE DATA
We used the Side effect Resource (SIDER) version 4.1.
SIDER contains information on marketed medicines and their
recorded side effects [26]. The information comes from pub-
lic documents and package inserts collected from the Food
and Drug Administration (FDA), Health Canada, European
Medicines Agency (EMA), etc. The version 4.1 contains more
than 1,500 marketed drugs and 5,868 side effects whose terms
are mapped in the Medical Dictionary for Regulatory Activ-
ities (MedDRA). The database integrates data from pre- and
post-marketing side effect evidence. A pictorial representation
of the data is presented in Figure 2 which shows the twenty
most popular side effects of marketed drugs.
Following Cami et al. [10], we used the drug-side effect
as binary associations. First, we only considered the side
effect terms that were MedDRA preferred terms (PT). Then,
we filtered out the drugs that have less than 5 side effects
and the side effect terms that were in less than 5 drugs.
This step is important because the method requires some data
for each drug and side effect to make confident prediction.
Similar filtering is performed when building datasets for movie
recommendations, where only users that have watched at least
20 movies are considered1. Thus, we obtained a gold-standard
data set that contains 1,525 marketed drugs and 2,050 side
effects with 148,705 known associations (i.e. density 4.75%).
nauseadermatitis
headache
vomiting
rash
dizziness
diarrhoea
pruritus
asthenia
hypersensitivity
abdominal pain
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body temperature increased
gastrointestinal pain
pain
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Fig. 2: WordCloud of the most popular side effect terms.
The 20 most popular side effects are shown. The size of the
word is proportional to the popularity of the side effect across
the corpus of drugs. The five most popular side effects are
indicated in orange.
IV. RESULTS
In this section we present the results of the experiments
with the proposed model. We followed the ten-fold cross
1https://grouplens.org/datasets/movielens/
validation procedure to find the optimal values for the reg-
ularization term (λ) and the number of hidden represen-
tations (k). We run the training with parameter values in
the set k ∈ {1, 5, 10, 15, 20, 25, 30, 35, 40, 50, 100} and λ ∈
{0.1, 1, 5, 10, 15, 20}. The training took roughly four hours in
a computer cluster of 12 cores (Intel(R) Zeon(R) CPU E5-
1650 v3 @ 3.5GHz). We found that the optimal number of
parameters were (kop = 40, λop = 15).
A. Latent factor models outperform PPNs
We trained our latent factor model and the network-based
method PPN-NET with 90% of the data and tested on the
remaining 10% of the data, i.e. 14,871 unseen drug-side effect
associations using the optimal parameters. Figure 3 shows
the precision-recall curve for the methods. Our latent factor
model outperforms PPNs in precision-recall in Area Under
the Precision-Recall Curve (AUPRC). Our model achieved
0.342 in AUPRC whereas PPN-NET achieved 0.282. In Area
Under the ROC Curve (AUROC), both models achieved 0.952.
Our model provides sensitivity of 0.73 at a specificity of
0.95. The curve also shows that our model performs better
in regions of high precision. For instance, we achieved a
recall of 20% at 70% precision, 10% higher than PPN-NET.
This is particularly important for ranked recommendations of
side effects. Furthermore, AUPRC is sometimes a more useful
measure when there the dataset is imbalanced [8], [27].
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Fig. 3: Precision-recall (PR) curve of the proposed method
and PPN-NET on the test set T test. Precision is the fraction of
retrieved instances that are relevant, while recall is the fraction
of relevant instances that are retrieved.
To understand the performance of our method in the binary
classification problem of identifying true from false drug-side
effect associations, we plotted in Figure 4 the distributions
of the predicted scores with respect to the binary classes for
the unseen drug-side effect associations in the test set T test.
The forty latent variables were able to capture complex hidden
relationships between the drugs and side effects that allowed
to fill in the incomplete matrix R. These latent features can
be interpreted as a low-dimensionality reduction on the orig-
inal associations. Clearly, the scores for the true associations
were significantly higher than for the false associations (t-test
significant, P < 4.94× 10−324).
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Fig. 4: Comparative violin plot of the predicted scores versus
the classes in the test set T test. The classes represent the
true and false drug-side effects associations. In both cases,
the predicted score for the true associations is higher than for
the false associations. For all side effects, mean and standard
deviation 0.361± 0.261 (true associations) vs 0.0396± 0.114
(false associations).
B. Drug- and side effect-specific predictions
An interesting question is whether the prediction perfor-
mance depends on drug- or side effect-specific category [10].
Drugs were classified using their Anatomical Therapeutic and
Chemical (ATC) categories. These categories are controlled
and curated by the World Health Organization (WHO)2. In
the ATC system, drugs are classified in a hierarchy of five
different levels. The system has fourteen main anatomical and
pharmacological groups on the first level, as shown in Table I.
We observed that the performance varies across therapeutic
categories (Figure 5), particularly higher for systemic hor-
monal preparations, insulin (H) drugs and lower for Blood
system (B) drugs. The drug-specific category performance
implies that it is more difficult to obtain accurate ranked
recommendation of side effects with high precision for certain
2https://www.whocc.no/atc ddd index/
therapeutics more than others, such as Blood system drugs
(40% precision at 20% recall) and dermatological drugs (52%
precision at 20% recall).
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Fig. 5: Precision-recall curve for drug-specific Anatomical
Therapeutic and Chemical (ATC) category. Only first level
ATC categories are shown. Different drugs have different
anatomical and pharmacological mode of action as represented
in this level.
TABLE I: Performance by drug-specific category
Top Performance
ATC category AUPRC
Alimentary tract and metabolism (A) 0.340
Blood and blood forming organs (B) 0.218a
Cardiovascular system (C) 0.358
Dermatologicals (D) 0.274
Genito urinary system and sex hormones (G) 0.346
Systemic hormonal preparations, insulins (H) 0.442b
Antiinfectives for systemic use (J) 0.340
Antineoplastic and immunomodulating agents (L) 0.354
Musculo-squeletal system (M) 0.369
Nervous system (N) 0.397
Antiparasitic products, insecticides and repellents (P) 0.299
Respiratory system (R) 0.328
Sensory organs (S) 0.315
Various (V) 0.218a
a,bLowest and highest performance.
Side effects were classified according to their top MedDRA
category of disorders. MedDRA is a rich and highly spe-
cific standardised medical terminology to facilitate sharing of
regulatory information internationally for medical products3.
It is curated by the International Council for Harmonisation
of Technical Requirements for Pharmaceuticals for Human
3https://www.meddra.org/
Use (ICH). We analyze the side effect-specific MedDRA
category as shown in Table II. We observed that the prediction
performance for side effect categories varies as well. The
highest performance was obtained for gastrointestinal disor-
ders whereas the lowest performance was obtained for side
effects related to neoplasms benign, malignant and unspecified
(including cysts and polyps).
To understand better the variability in performance by side
effect category, we show in Figure 6 a representative set
of MedDRA categories. As mention before, gastrointestinal
side effects are easier to recall with high precision, i.e. by
70% precision at 30% recall, whereas neoplasms represent a
somewhat harder problem, by 10% precision at 30% recall.
Interestingly, disorders related to the immune system such as
autoimmune disorders including nervous, muscular, hepatic
and lupus-associated conditions achieved a relatively good
performance (40% precision at 30% recall).
TABLE II: Performance by side effect-specific category
Top Performance
MEDDRA category AUPRC
Hepatobiliary disorders 0.170
Metabolism and nutrition disorders 0.275
Eye disorders 0.187
Investigations 0.192
Musculoskeletal and connective tissue disorders 0.351
Gastrointestinal disorders 0.448b
Social circumstances 0.245
Immune system disorders 0.297
Reproductive system and breast disorders 0.186
Neoplasms 0.064a
General disorders and administration site conditions 0.432
Endocrine disorders 0.163
Vascular disorders 0.332
Blood and lymphatic system disorders 0.272
Skin and subcutaneous tissue disorders 0.381
Congenital, familial and genetic disorders 0.185
Infections and infestations 0.303
Respiratory, thoracic and mediastinal disorders 0.301
Psychiatric disorders 0.352
Renal and urinary disorders 0.269
Ear and labyrinth disorders 0.358
Cardiac disorders 0.363
Nervous system disorders 0.370
Injury, poisoning and procedural complications 0.122
a,bLowest and highest performance.
V. CONCLUSION AND DISCUSSION
In silico side effect prediction can help safety professionals
to prioritize candidates in pharmacoepidemiological studies
and to anticipate possible lethal outcomes [1], [10], [19]. It has
shown already useful in toxicology and drug safety, but there
are still many unanswered questions in the emerging field of
computational pharmacology [28], such as the characterization
of the incomplete drug-target networks and the prediction of
lethal polypharmacy side effects [1]. The first is important to
understand the soff-target proteins that cause the side effect
[19], whereas the latter because most treatments consist of
drug combinations that can lead to unseen and unpredictable
side effects.
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Fig. 6: Precision-recall curve for different side effect-specific
MedDRA category. Only a representative number of top
MedDRA disorders are shown.
In this paper, we investigated the use of collaborative
filtering models for predicting side effects of marketed drugs.
We trained a latent factor model on safety data from public
package inserts that included 1,525 marketed drugs and 2,050
side effect unique terms. The proposed model achieved an
AUPRC of 0.342 and an AUROC of 0.952 in a hold-out
test set, with a sensitivity of 0.73 given a specificity of 0.95.
Our findings suggest that latent factor models can be useful
for predicting side effects of marketed drugs. Our method
offers an alternative and efficient approach for exploring drug
safety profiles on marketed drugs. We showed that our method
outperforms the network-based method PPNs in AUPRC,
which is of particular importance when using ranked recom-
mendations of drug side effects. Furthermore, we analyzed the
performances on drug-and side effect-specific categories. We
found that there is better performance for some categories than
for others.
There is still room for improvement in predicting and
understanding drug side effects in the emerging field of system
pharmacology. Importantly, in silico side effect prediction
methods can be used as a complement to the wide range of in
vitro or in vivo approaches to anticipate and detect toxicolog-
ical liabilities in pre-and post-marketing drug development.
ACKNOWLEDGMENT
The authors would like to thank the anonymous review-
ers for their valuable comments and suggestions to improve
the quality of the paper. A.P. and D.G. were supported
in part by Biotechnology and Biological Sciences Research
Council (BBSRC), grants BB/K004131/1, BB/F00964X/1 and
BB/M025047/1 to A.P., CONACYT Paraguay Grant INVG01-
112 (14-INV-088) and PINV15-315 (14-INV-088), and NSF
Advances in Bio Informatics grant 1660648.
REFERENCES
[1] N. P. Tatonetti, P. Y. Patrick, R. Daneshjou, and R. B. Altman, “Data-
driven prediction of drug effects and interactions,” Science translational
medicine, vol. 4, no. 125, pp. 125ra31–125ra31, 2012.
[2] J. H. Gurwitz, T. S. Field, J. Avorn, D. McCormick, S. Jain, M. Eckler,
M. Benser, A. C. Edmondson, and D. W. Bates, “Incidence and
preventability of adverse drug events in nursing homes,” The American
journal of medicine, vol. 109, no. 2, pp. 87–94, 2000.
[3] F. R. Ernst and A. J. Grizzle, “Drug-related morbidity and mortality:
updating the cost-of-illness model,” Journal of the American Pharma-
ceutical Association (1996), vol. 41, no. 2, pp. 192–199, 2001.
[4] H. C. J. . A. J. K. Onakpoya, I. J., “Post-marketing withdrawal of
462 medicinal products because of adverse drug reactions: a systematic
review of the world literature.” BMC Medicine, 2016.
[5] C. Vanchieri, “Vioxx withdrawal alarms cancer prevention researchers,”
Journal of the National Cancer Institute, vol. 96, no. 23, pp. 1734–1735,
2004.
[6] Dearden, “In silico prediction of drug toxicity,” Comput Aided Mol Des,
2003.
[7] E. Lounkine, M. J. Keiser, S. Whitebread, D. Mikhailov, J. Hamon, J. L.
Jenkins, P. Lavan, E. Weber, A. K. Doak, S. Coˆte´ et al., “Large-scale
prediction and testing of drug activity on side-effect targets,” Nature,
vol. 486, no. 7403, pp. 361–367, 2012.
[8] Y. Yamanishi, E. Pauwels, and M. Kotera, “Drug side-effect prediction
based on the integration of chemical and biological spaces,” Journal of
chemical information and modeling, vol. 52, no. 12, pp. 3284–3292,
2012.
[9] M. X. LaBute, X. Zhang, J. Lenderman, B. J. Bennion, S. E. Wong, and
F. C. Lightstone, “Adverse drug reaction prediction using scores pro-
duced by large-scale drug-protein target docking on high-performance
computing machines,” PloS one, vol. 9, no. 9, p. e106298, 2014.
[10] A. Cami, A. Arnold, S. Manzi, and B. Reis, “Predicting adverse drug
events using pharmacological network models,” Science translational
medicine, vol. 3, no. 114, pp. 114ra127–114ra127, 2011.
[11] I. Shaked, M. A. Oberhardt, N. Atias, R. Sharan, and E. Ruppin,
“Metabolic network prediction of drug side effects,” Cell systems, vol. 2,
no. 3, pp. 209–213, 2016.
[12] M. J. Keiser, V. Setola, J. J. Irwin, C. Laggner, A. I. Abbas, S. J.
Hufeisen, N. H. Jensen, M. B. Kuijer, R. C. Matos, T. B. Tran et al.,
“Predicting new molecular targets for known drugs,” Nature, vol. 462,
no. 7270, p. 175, 2009.
[13] J. T. Dudley, T. Deshpande, and A. J. Butte, “Exploiting drug–disease
relationships for computational drug repositioning,” Briefings in bioin-
formatics, vol. 12, no. 4, pp. 303–311, 2011.
[14] R. M. Bell and Y. Koren, “Lessons from the netflix prize challenge,”
Acm Sigkdd Explorations Newsletter, vol. 9, no. 2, pp. 75–79, 2007.
[15] Y. Koren, R. Bell, and C. Volinsky, “Matrix factorization techniques for
recommender systems,” Computer, vol. 42, no. 8, 2009.
[16] Y. Hu, Y. Koren, and C. Volinsky, “Collaborative filtering for implicit
feedback datasets,” in Data Mining, 2008. ICDM’08. Eighth IEEE
International Conference on. Ieee, 2008, pp. 263–272.
[17] P. Cremonesi, Y. Koren, and R. Turrin, “Performance of recommender
algorithms on top-n recommendation tasks,” in Proceedings of the fourth
ACM conference on Recommender systems. ACM, 2010, pp. 39–46.
[18] Y. Kwon, Handbook of essential pharmacokinetics, pharmacodynamics
and drug metabolism for industrial scientists. Springer Science &
Business Media, 2001.
[19] M. Campillos, M. Kuhn, A.-C. Gavin, L. J. Jensen, and P. Bork, “Drug
target identification using side-effect similarity,” Science, vol. 321, no.
5886, pp. 263–266, 2008.
[20] M. Kuhn, M. Campillos, I. Letunic, L. J. Jensen, and P. Bork, “A
side effect resource to capture phenotypic effects of drugs,” Molecular
systems biology, vol. 6, no. 1, p. 343, 2010.
[21] C. C. Aggarwal, Recommender systems. Springer, 2016.
[22] Rassmusen. (2006, 04) Minimize. [Online]. Available: http://learning.
eng.cam.ac.uk/carl/code/minimize/
[23] J. L. Herlocker, J. A. Konstan, L. G. Terveen, and J. T. Riedl, “Evaluating
collaborative filtering recommender systems,” ACM Transactions on
Information Systems (TOIS), vol. 22, no. 1, pp. 5–53, 2004.
[24] X. Su and T. M. Khoshgoftaar, “A survey of collaborative filtering
techniques,” Advances in artificial intelligence, vol. 2009, p. 4, 2009.
[25] F. Ricci, L. Rokach, and B. Shapira, “Introduction to recommender
systems handbook,” in Recommender systems handbook. Springer,
2011, pp. 1–35.
[26] M. Kuhn, I. Letunic, L. J. Jensen, and P. Bork, “The sider database
of drugs and side effects,” Nucleic acids research, vol. 44, no. D1, pp.
D1075–D1079, 2015.
[27] N. Atias and R. Sharan, “An algorithmic framework for predicting side
effects of drugs,” Journal of Computational Biology, vol. 18, no. 3, pp.
207–218, 2011.
[28] A. L. Hopkins, “Network pharmacology,” Nature biotechnology, vol. 25,
no. 10, p. 1110, 2007.
